Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 14

Results For "CNS"

133 News Found

Lupin launches generic version of Brovana in US
News | June 04, 2021

Lupin launches generic version of Brovana in US

Arformoterol Tartrate Inhalation Solution is for treatment of bronchoconstriction

Marksans Pharma Q4 FY21 profit up 86%
News | June 01, 2021

Marksans Pharma Q4 FY21 profit up 86%

The company's operating revenue for Q4 FY21 was Rs. 330.2 crore

Lupin receives US $50 mn on achieving cancer milestone
News | May 28, 2021

Lupin receives US $50 mn on achieving cancer milestone

MEK inhibitor compound (LNP3794) developed as part of its oncology pipeline had previously shown pre-clinical activity as a single agent as well as in combination

Latest Stories

NIPER Mohali, Novartis Healthcare sign pact to boost pharma R&D innovation

Rubicon forays into India's CNS segment with Rs 175.92 crore Arinna buy

Zydus Wellness appoints Adhir Anand as Head of Media & Digital

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
Only 4-5 Indian pharma companies have a strong presence in Russia, opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia, opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Companies must shift from L1 costing to Life Cycle Cost Analysis: Abhilash Pasham, Associate GM - Central Engineering & Projects, Dr. Reddy's Laboratories
Companies must shift from L1 costing to Life Cycle Cost Analysis: Abhilash Pasham, Associate GM - Central Engineering & Projects, Dr. Reddy's Laboratories

Packaging